Cetuximab (Erbitux®) is a DNA recombinant mAb that binds selectively to the extracellular domain of EGFR (encoded by HER-1) with a 5 to 10-times higher affinity than endogenous ligands, inhibiting the EGFR pathway and tumor growth. This evidence concerns the gene EGFR and neoplasm.